Molecular profiling of basal cell carcinomas in young patients.
Basal cell carcinoma
NGS
NMSC
PTCH1
TP53
Journal
BMC medical genomics
ISSN: 1755-8794
Titre abrégé: BMC Med Genomics
Pays: England
ID NLM: 101319628
Informations de publication
Date de publication:
20 07 2021
20 07 2021
Historique:
received:
21
08
2020
accepted:
05
07
2021
entrez:
21
7
2021
pubmed:
22
7
2021
medline:
20
1
2022
Statut:
epublish
Résumé
Basal cell carcinoma (BCC) represents by far the most common non-melanoma skin cancer (NMSC) in the world with an increasing incidence of 3% to 10% per year, especially in patients under the age of 40. While variants in the sonic Hedgehog and cell cycle regulation pathways account for the majority of BCC cases in adults, the molecular etiology of BCC in young patients is unelucidated yet. This study aims to investigate the molecular profile of BCC in the young population. 28 tumors belonging to 25 Lebanese patients under the age of 40, presenting different stages of BCC and diagnosed at Hôtel Dieu de France-Saint Joseph University Medical Center were included in this study. A selected panel of 150 genes involved in cancer was analyzed by Next Generation Sequencing (NGS) in the 28 included tumors. Genetic variants detected in more than 5% of the reads, with a sequencing depth ≥ 50x, were selected. Two hundred and two genetic variants in 48 different genes were detected, with an overall average sequencing depth of 1069x. Among the 28 studied tumors, 18 (64.3%) show variations in the PTCH1 gene, 6 (21.4%) in TP53 and 3 (10.7%) in SMO. This is the first study reporting NGS-based analysis of BCC in a cohort of young patients. Our results highlight the involvement of the hedgehog and cell cycle regulation pathways in the genesis of BCC in the general population. The inclusion of a larger cohort of young patients is needed to confirm our findings.
Sections du résumé
BACKGROUND
Basal cell carcinoma (BCC) represents by far the most common non-melanoma skin cancer (NMSC) in the world with an increasing incidence of 3% to 10% per year, especially in patients under the age of 40. While variants in the sonic Hedgehog and cell cycle regulation pathways account for the majority of BCC cases in adults, the molecular etiology of BCC in young patients is unelucidated yet. This study aims to investigate the molecular profile of BCC in the young population.
METHODS
28 tumors belonging to 25 Lebanese patients under the age of 40, presenting different stages of BCC and diagnosed at Hôtel Dieu de France-Saint Joseph University Medical Center were included in this study. A selected panel of 150 genes involved in cancer was analyzed by Next Generation Sequencing (NGS) in the 28 included tumors.
RESULTS
Genetic variants detected in more than 5% of the reads, with a sequencing depth ≥ 50x, were selected. Two hundred and two genetic variants in 48 different genes were detected, with an overall average sequencing depth of 1069x. Among the 28 studied tumors, 18 (64.3%) show variations in the PTCH1 gene, 6 (21.4%) in TP53 and 3 (10.7%) in SMO.
CONCLUSIONS
This is the first study reporting NGS-based analysis of BCC in a cohort of young patients. Our results highlight the involvement of the hedgehog and cell cycle regulation pathways in the genesis of BCC in the general population. The inclusion of a larger cohort of young patients is needed to confirm our findings.
Identifiants
pubmed: 34284772
doi: 10.1186/s12920-021-01030-w
pii: 10.1186/s12920-021-01030-w
pmc: PMC8293576
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
187Informations de copyright
© 2021. The Author(s).
Références
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
Clin Genet. 2015 Sep;88(3):273-7
pubmed: 25080371
Am J Clin Pathol. 2015 Jun;143(6):901-4
pubmed: 25972334
Nucleic Acids Res. 2002 Mar 15;30(6):1354-63
pubmed: 11884633
Sci Rep. 2020 May 14;10(1):8005
pubmed: 32409749
Nature. 1998 Jan 1;391(6662):90-2
pubmed: 9422511
Br J Cancer. 2014 Jul 8;111(1):203-6
pubmed: 24874476
Nat Genet. 2011 May;43(5):491-8
pubmed: 21478889
Int J Dermatol. 2010 Sep;49(9):978-86
pubmed: 20883261
JAMA Dermatol. 2015 Sep;151(9):976-81
pubmed: 26039887
Bioinformatics. 2009 Nov 1;25(21):2744-50
pubmed: 19734154
Mutat Res. 2005 Apr 1;571(1-2):19-31
pubmed: 15748635
JCI Insight. 2018 Aug 9;3(15):
pubmed: 30089731
J Dermatolog Treat. 2020 Jun;31(4):387-398
pubmed: 31039644
N Engl J Med. 2005 Nov 24;353(21):2262-9
pubmed: 16306523
Nature. 1993 Apr 22;362(6422):709-15
pubmed: 8469282
J Invest Dermatol. 2013 Apr;133(4):913-8
pubmed: 23190883
Nat Rev Cancer. 2008 Oct;8(10):743-54
pubmed: 18813320
Genome Res. 2010 Sep;20(9):1297-303
pubmed: 20644199
Br J Dermatol. 2002 Apr;146 Suppl 61:17-9
pubmed: 11966727
BMC Med Genomics. 2014 May 13;7:23
pubmed: 24885028
Br J Dermatol. 2005 Jan;152(1):43-51
pubmed: 15656799
J Invest Dermatol. 2014 Oct;134(10):2491-2493
pubmed: 25219650
Br J Dermatol. 2002 Apr;146 Suppl 61:1-6
pubmed: 11966724
J Photochem Photobiol B. 2001 Oct;63(1-3):8-18
pubmed: 11684447
Nucleic Acids Res. 2018 Jul 2;46(W1):W545-W553
pubmed: 29860484
Ann Saudi Med. 2013 May-Jun;33(3):304-6
pubmed: 23793437
J Mol Diagn. 2017 Jan;19(1):4-23
pubmed: 27993330
J Invest Dermatol. 2004 Oct;123(4):634-8
pubmed: 15373766
J Cutan Pathol. 2002 May;29(5):287-90
pubmed: 12100629
Nat Genet. 2016 Apr;48(4):398-406
pubmed: 26950094
J Invest Dermatol. 2014 Jan;134(1):213-220
pubmed: 23774526